Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 308

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 308
---
 align='center'>162</div>

TABLE OF CONTENTS

more than an aggregate of 15% of the shares sold in Iris’s IPO, without Iris’s prior consent. Accordingly, if a public stockholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the shares sold in Iris’s IPO, then any such shares in excess of that 15% limit would not be redeemed for cash, without Iris’s prior consent.

In order for public stockholders to exercise their redemption rights in respect of the Business Combination Proposal, public stockholders must properly exercise their redemption rights and deliver their stock certificates or shares of stock (electronically using The Depository Trust Company’s DWAC (Deposit/ Withdrawal At Custodian) system) to Iris’s Transfer Agent prior to , Eastern Time, on , 2025 (two business days prior to the vote on the proposal to approve the Business Combination). Promptly following the consummation of the Business Combination, Iris will satisfy the exercise of redemption rights by redeeming the shares of Iris Class A Common Stock issued to the public stockholders that validly exercised their redemption rights.

If the Business Combination is not consummated, shares submitted for redemption will not be redeemed for cash.

Holders of warrants will not have redemption rights with respect to the warrants.

### Liquidation if No Business Combination
Iris will have only 51 months from the closing of the IPO to complete the initial business combination. However, if Iris is unable to complete the initial business combination or amend the Iris Certificate of Incorporation within that time period, Iris will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (which interest shall be net of all applicable taxes payable from the Trust Account and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish the public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of Iris’s remaining stockholders and the Iris Board, liquidate and dissolve, subject, in each case, to Iris’s